A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1461-1463

  Assikis, V J ^a   Neven, P ^b   Jordan, V C ^c   Vergote, I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Saint Jean Clinic of Brussels   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anti oestrogens; Breast cancer; Carcinogenicity; Endometrial cancer; Tamoxifen

Indexed keywords

EID: 33748456978     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths in 75000 women. Lancet 1992, 339, 1-15,71-85.
2. Furr BA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984, 25, 127-205.
3. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 1994, 31, 5-9.
4. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992, 326, 852-856.
5. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994, 12, 992-997.
6. Bilimoria MM, Assikis VJ, Jordan VC. Should adjuvant tamoxifen therapy be stopped at 5 years? Cancer J Sci Am, 1996,2, 140-150.
7. Boccardo F, Guarneri D, Rubagotti A, et al. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984, 70, 61-68.
8. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BrJMed 1995, 311, 977-980.
9. Neven P, DeMuylder X, VanBelle Y, et al. Tamoxifen and the uterus and endometrium. Lancet 1989, i, 375.
10. Anonymous. IARC way of assessing tamoxifen causes unease. Lancet 1996, 347, 458.
11. Love RR. Tamoxifen in healthy premenopausal and postmenopausal women: different risks and benefits. J Natl Cancer Inst 1994,86,62-63.
12. Neven P, DeMuylder X, VanBelle Y, et al. Tamoxifen and the uterus. BrJMed 1994, 309, 1313-1314.
13. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991, 83, 1278-1280.
14. Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994, 31, 73-82.
15. Vanchieri C. Breast cancer study initiated in Italy. J Natl Cancer Inst 1992, 84, 1555-1556.
16. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985, 69, 237-238.
17. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Im J Gynecol Obstet 1995,49,241-257.
18. Tucker MJ, Adams HK, Patterson JS. In Laurence DR, McLean AEM, Weatherall M, eds. Safety Testing of New Drugs. New York, Academic Press, 1984, 125-161.
19. Yager JD, Roebuch BD, Paluszcyk TL, et al. Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis 1986, 7, 2007-2014.
20. Hirsimaki P, Hirsimaki Y, Nieminen L, et al. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol 1993, 67, 49-54.
21. Williams GM, latropoulos MJ, Djordjevic MV, et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993, 14, 315-317.
22. Greaves P, Goonetilleke R, Nunn G, et al. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993, 53, 3919-3924.
23. Carthew P, Rich KJ, Martin EA, et al. DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumor formation. Carcinogenesis 1995, 16, 1299-1304.
24. White INH, De Matteis F, Davies A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992, 13,2197-2203.
25. Han X, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992, 52, 1360-1363.
26. Hard GC, latropoulos MJ, Jordan K, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female CrhCD(BR) rats. Cancer Res 1993, 53, 4534-4541.
27. Dragan YP, Fahey S, Street K, et al. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat 1994, 31, 11-25.
28. Montandon F, Williams GM. Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch Toxicol 1994,68,272-275.
29. Jordan VC. Fourteenth Gaddurn Memorial Lecture: a current view of tamoxifen for the treatment and prevention of breast cancer. Br JPharmacol 1993, 110, 507-517.
30. Tucker MJ, Adam HK, Patterson JS. Tamoxifen. In Lawrence DR, McLean AEM, Weatherall M, eds. Safety Testing of New Drugs. Academic Press, New York, 1984.
31. Styles JA, Davies A, Lim CK, et al. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 1994, 15, 5-9.
32. Pathak DN, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 1994,15,529-532.
33. Martin EA, Rich KJ, White INH, et al. 12P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995, 16, 1651-1654.
34. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? EurJ Cancer 1994, 30A, 1714-1721.
35. Muir C. Cancer incidence in five continents. IARC Scientific Publications, Vol V, No. 88. Lyon, France, International Agency for Research in Cancer, 1987.
36. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989, 1, 117-120.
37. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995, 87, 645-651.
38. Muhleman K, Cook LS, Weiss NS. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res Treat 1994, 30,201-204.
39. Prentice RL. Epidemiologic data on exogeneous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 1991,20,38-46.
40. Carmichael PL, Ugwumadu AHN, Neven P, et al. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996,56, 1475-1479.
41. Satyaswaroop PG, Zaino RJ, Mörtel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984, 44, 4006-4010.
42. Gottardis MM, Robinson SP, Satyaswaroop PG, et al. Contrasting action of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988, 48, 812-815.
43. Neven P, DeMuylder X, VanBelle Y, et al. Hysteroscopic followup during tamoxifen treatment. Eur J Obstet Gynaecol Rep Biol 1990,35,235-238.
44. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994, 47, 827-833.
45. Lahti E, Blanco G, Kaupilla A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993, 81, 660-664.
46. Nuovo MA, Nuovo GJ, McCaffrey RM, et al. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Par/zo/1989, 8, 125-131.
47. Horowitz RI, Feinstein AR. Estrogens and endometrial cancer. Am J Med 1986, 81, 503-507.
48. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-1982. Nad Cancer Inst Monogr 1985, 68,99-112.
49. Teppo L, Pukkala E, Saxen E. Multiple cancer-an epidemiologic exercise in Finland. J Natl Cancer Inst 1985, 75, 207-217.
50. Adami HO, Krusemo UB, Bergkvist L, et al. On the age-dependent association between cancer of the breast and of the endometrium. A nationwide cohort study. Br J Cancer 1987, 55, 77-80.
51. Bokhman JB, Maximov SJ. Relative risk of development and active detection of primary multiple endometrial, breast and ovarian cancer. EurJ Gynaecol Oncol 1993, 14, 114-118.
52. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol 1995, 58, 198-201.
53. Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Nail Cancer Inst 1993,85, 1850-1855.
54. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. JNatl Cancer Inst 1994, 86, 527-537.
55. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995, 1, 467-472.
56. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radio-therapy for early breast cancer. J Natl Cancer Inst 1991, 83, 1013-1017.
57. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992, 31, 259-263.
58. Stewart HJ. The Scottish trial of adjuvant tamoxifen in nodenegative breast cancer. Monogr Natl Cancer Inst 1992, 11, 1 IT120.
59. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. Monogr Nad Cancer Inst 1992, 11, 121-125.
60. Magriples U, Naftolin F, Schwanz PE, et al. High-grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 1993, 11, 485-490.
61. National Cancer Institute. SEER Cancer Statistics Review 1973-1990, Document 93-2789. Bethesda, Maryland, NCI, 1993.
62. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994, 343, 448-452.
63. Barakat RR, Wong G, Curtin JP, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994, 55, 164-168.
64. Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. JNatl Cancer Inst 1995, 87, 1359-1364.
65. Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995, 59, 186-190.
66. Jordan VC. What if tamoxifen (ICI 46,474) had been found to produce liver tumors in 1973? Ann Oncol 1995, 6, 29-34.
67. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994, 343, 1318-1321.
68. Gibson LE, Barakat RR, Venkatraman ES, et al. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Cancer J Sci Am 1996,2,35-38.
69. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994, 170, 447-451.
70. Neven P. Endometrial changes in patients on tamoxifen. Lancet 1995, 346, 1292.
71. De Muylder X, Neven P, VanBelle Y, et al. Endometrial lesions in patients undergoing tamoxifen therapy. Im J Gynaecol Obstet 1991,36, 127-130.
72. Pritchard K, Meakin JW, Boyd NF. Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. An update. In Salmon SE, éd. Adjuvant Therapy of Cancer, Vol. V. Orlando, Grune and Stratum, 1987, 391-400.
73. NATO (Nolvadex Adjuvant Trial Organization). Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Analysis at eight years by the Nolvadex Adjuvant Trial Organization. BrJCancer 1988, 57, 608-611.
74. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993, 11, 29-35.
75. Decensi A, Fontana V, Bruno S, et al. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996, 14, 434-440.